Resources
6 whitepapers from Mumbai Biocluster and summit sessions. Sign in to view or download the full PDFs.
A policy roundtable with academia, industry, investors and funders, including ICMR and DBT, on how coordinated funding and regulatory alignment can accelerate adoption of NAMs in India's R&D ecosystem.
22 Jan 2026 · PDF · 13.7 MB
How organ-on-a-chip and microphysiological systems can address clinical drug failure, the regulatory inflection point following the FDA Modernization Act, and the move from simple mini-organs to multi-organ platforms with continuous, non-invasive monitoring.
22 Jan 2026 · PDF · 2.4 MB
Examines how high clinical attrition stems from poor translational predictivity of 2D cultures and some animal models. Covers 3D tumoroids that capture microenvironment-driven drug resistance and human iPSC-derived platforms, such as cardiomyocytes, as scalable, regulatory-relevant New Approach Methodologies.
22 Jan 2026 · PDF · 30.0 MB
How 3D bioprinting is moving beyond laboratory prototypes toward clinically translatable and industrially scalable solutions, including tissue-specific bioinks and microfluidic culture systems.
22 Jan 2026 · PDF · 2.7 MB
As regulators reform the use of animals in drug development, this session looks at how artificial intelligence and machine learning can support the development and adoption of New Approach Methodologies built on 3D cell culture.
22 Jan 2026 · PDF · 2.7 MB
The scientific, regulatory and implementation challenges shaping adoption of NAMs in drug development and biologics research, with particular relevance to India's evolving regulatory and innovation landscape.
22 Jan 2026 · PDF · 2.5 MB